This year, Negrao et al. from the Anderson Cancer Center25 reported that NF1 mutant/high tumor mutational burden (TMB) NSCLC patients had longer progression‐free survival than NF1 wild‐type/high TMB NSCLC patients in a large‐scale study of PD‐L1 immune checkpoint inhibitor therapy. The gene discussed is NF1; the disease is neoplasm.